Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing

Daniela S. Basseres, Francesco D'Alò, Beow Y. Yeap, Ester C. Löwenberg, David A. Gonzalez, Hiroyuki Yasuda, Tajhal Dayaram, Olivier N. Kocher, John J. Godleski, William G. Richards, Matthew Meyerson, Susumu Kobayashi, Daniel G. Tenen, Balazs Halmos, Daniel B. Costa

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC). Methods: A series of 25 lung cancer cell lines were evaluated for Foxa2 protein expression, FOXA2 mRNA levels, FOXA2 mutations, FOXA2 copy number changes and for evidence of FOXA2 promoter hypermethylation. In addition, 32 NSCLCs were sequenced for FOXA2 mutations and 173 primary NSCLC tumors evaluated for Foxa2 expression using an immunohistochemical assay. Results: Out of the 25 cell lines, 13 (52%) had undetectable FOXA2 mRNA. The expression of FOXA2 mRNA and Foxa2 protein were congruent in 19/22 cells (p= 0.001). FOXA2 mutations were not identified in primary NSCLCs and were infrequent in cell lines. Focal or broad chromosomal deletions involving FOXA2 were not present. The promoter region of FOXA2 had evidence of hypermethylation, with an inverse correlation between FOXA2 mRNA expression and presence of CpG dinucleotide methylation (p< 0.0001). In primary NSCLC tumor specimens, there was a high frequency of either absence (42/173, 24.2%) or no/low expression (96/173, 55.4%) of Foxa2. In 130 patients with stage I NSCLC there was a trend towards decreased survival in tumors with no/low expression of Foxa2 (HR of 1.6, 95%CI 0.9-3.1; p= 0.122). Conclusions: Loss of expression of Foxa2 is frequent in lung cancer cell lines and NSCLCs. The main mechanism of downregulation of Foxa2 is epigenetic silencing through promoter hypermethylation. Further elucidation of the involvement of Foxa2 and other airway transcription factors in the pathogenesis of lung cancer may identify novel therapeutic targets.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalLung Cancer
Volume77
Issue number1
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Epigenomics
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Transcription Factors
Down-Regulation
Cell Line
Messenger RNA
Mutation
Neoplasms
Genetic Promoter Regions
Methylation
Proteins
Survival
Therapeutics

Keywords

  • Adenocarcinoma
  • Downregulation
  • Epigenetic
  • Foxa2
  • Lung cancer
  • Methylation
  • Mutation
  • Non-small-cell lung cancer
  • Prognosis
  • Transcription factors

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Basseres, D. S., D'Alò, F., Yeap, B. Y., Löwenberg, E. C., Gonzalez, D. A., Yasuda, H., ... Costa, D. B. (2012). Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer, 77(1), 31-37. https://doi.org/10.1016/j.lungcan.2012.01.011

Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. / Basseres, Daniela S.; D'Alò, Francesco; Yeap, Beow Y.; Löwenberg, Ester C.; Gonzalez, David A.; Yasuda, Hiroyuki; Dayaram, Tajhal; Kocher, Olivier N.; Godleski, John J.; Richards, William G.; Meyerson, Matthew; Kobayashi, Susumu; Tenen, Daniel G.; Halmos, Balazs; Costa, Daniel B.

In: Lung Cancer, Vol. 77, No. 1, 07.2012, p. 31-37.

Research output: Contribution to journalArticle

Basseres, DS, D'Alò, F, Yeap, BY, Löwenberg, EC, Gonzalez, DA, Yasuda, H, Dayaram, T, Kocher, ON, Godleski, JJ, Richards, WG, Meyerson, M, Kobayashi, S, Tenen, DG, Halmos, B & Costa, DB 2012, 'Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing', Lung Cancer, vol. 77, no. 1, pp. 31-37. https://doi.org/10.1016/j.lungcan.2012.01.011
Basseres, Daniela S. ; D'Alò, Francesco ; Yeap, Beow Y. ; Löwenberg, Ester C. ; Gonzalez, David A. ; Yasuda, Hiroyuki ; Dayaram, Tajhal ; Kocher, Olivier N. ; Godleski, John J. ; Richards, William G. ; Meyerson, Matthew ; Kobayashi, Susumu ; Tenen, Daniel G. ; Halmos, Balazs ; Costa, Daniel B. / Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. In: Lung Cancer. 2012 ; Vol. 77, No. 1. pp. 31-37.
@article{805e02debda74e11a17a3e2fc1774f11,
title = "Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing",
abstract = "Purpose: We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC). Methods: A series of 25 lung cancer cell lines were evaluated for Foxa2 protein expression, FOXA2 mRNA levels, FOXA2 mutations, FOXA2 copy number changes and for evidence of FOXA2 promoter hypermethylation. In addition, 32 NSCLCs were sequenced for FOXA2 mutations and 173 primary NSCLC tumors evaluated for Foxa2 expression using an immunohistochemical assay. Results: Out of the 25 cell lines, 13 (52{\%}) had undetectable FOXA2 mRNA. The expression of FOXA2 mRNA and Foxa2 protein were congruent in 19/22 cells (p= 0.001). FOXA2 mutations were not identified in primary NSCLCs and were infrequent in cell lines. Focal or broad chromosomal deletions involving FOXA2 were not present. The promoter region of FOXA2 had evidence of hypermethylation, with an inverse correlation between FOXA2 mRNA expression and presence of CpG dinucleotide methylation (p< 0.0001). In primary NSCLC tumor specimens, there was a high frequency of either absence (42/173, 24.2{\%}) or no/low expression (96/173, 55.4{\%}) of Foxa2. In 130 patients with stage I NSCLC there was a trend towards decreased survival in tumors with no/low expression of Foxa2 (HR of 1.6, 95{\%}CI 0.9-3.1; p= 0.122). Conclusions: Loss of expression of Foxa2 is frequent in lung cancer cell lines and NSCLCs. The main mechanism of downregulation of Foxa2 is epigenetic silencing through promoter hypermethylation. Further elucidation of the involvement of Foxa2 and other airway transcription factors in the pathogenesis of lung cancer may identify novel therapeutic targets.",
keywords = "Adenocarcinoma, Downregulation, Epigenetic, Foxa2, Lung cancer, Methylation, Mutation, Non-small-cell lung cancer, Prognosis, Transcription factors",
author = "Basseres, {Daniela S.} and Francesco D'Al{\`o} and Yeap, {Beow Y.} and L{\"o}wenberg, {Ester C.} and Gonzalez, {David A.} and Hiroyuki Yasuda and Tajhal Dayaram and Kocher, {Olivier N.} and Godleski, {John J.} and Richards, {William G.} and Matthew Meyerson and Susumu Kobayashi and Tenen, {Daniel G.} and Balazs Halmos and Costa, {Daniel B.}",
year = "2012",
month = "7",
doi = "10.1016/j.lungcan.2012.01.011",
language = "English (US)",
volume = "77",
pages = "31--37",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing

AU - Basseres, Daniela S.

AU - D'Alò, Francesco

AU - Yeap, Beow Y.

AU - Löwenberg, Ester C.

AU - Gonzalez, David A.

AU - Yasuda, Hiroyuki

AU - Dayaram, Tajhal

AU - Kocher, Olivier N.

AU - Godleski, John J.

AU - Richards, William G.

AU - Meyerson, Matthew

AU - Kobayashi, Susumu

AU - Tenen, Daniel G.

AU - Halmos, Balazs

AU - Costa, Daniel B.

PY - 2012/7

Y1 - 2012/7

N2 - Purpose: We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC). Methods: A series of 25 lung cancer cell lines were evaluated for Foxa2 protein expression, FOXA2 mRNA levels, FOXA2 mutations, FOXA2 copy number changes and for evidence of FOXA2 promoter hypermethylation. In addition, 32 NSCLCs were sequenced for FOXA2 mutations and 173 primary NSCLC tumors evaluated for Foxa2 expression using an immunohistochemical assay. Results: Out of the 25 cell lines, 13 (52%) had undetectable FOXA2 mRNA. The expression of FOXA2 mRNA and Foxa2 protein were congruent in 19/22 cells (p= 0.001). FOXA2 mutations were not identified in primary NSCLCs and were infrequent in cell lines. Focal or broad chromosomal deletions involving FOXA2 were not present. The promoter region of FOXA2 had evidence of hypermethylation, with an inverse correlation between FOXA2 mRNA expression and presence of CpG dinucleotide methylation (p< 0.0001). In primary NSCLC tumor specimens, there was a high frequency of either absence (42/173, 24.2%) or no/low expression (96/173, 55.4%) of Foxa2. In 130 patients with stage I NSCLC there was a trend towards decreased survival in tumors with no/low expression of Foxa2 (HR of 1.6, 95%CI 0.9-3.1; p= 0.122). Conclusions: Loss of expression of Foxa2 is frequent in lung cancer cell lines and NSCLCs. The main mechanism of downregulation of Foxa2 is epigenetic silencing through promoter hypermethylation. Further elucidation of the involvement of Foxa2 and other airway transcription factors in the pathogenesis of lung cancer may identify novel therapeutic targets.

AB - Purpose: We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC). Methods: A series of 25 lung cancer cell lines were evaluated for Foxa2 protein expression, FOXA2 mRNA levels, FOXA2 mutations, FOXA2 copy number changes and for evidence of FOXA2 promoter hypermethylation. In addition, 32 NSCLCs were sequenced for FOXA2 mutations and 173 primary NSCLC tumors evaluated for Foxa2 expression using an immunohistochemical assay. Results: Out of the 25 cell lines, 13 (52%) had undetectable FOXA2 mRNA. The expression of FOXA2 mRNA and Foxa2 protein were congruent in 19/22 cells (p= 0.001). FOXA2 mutations were not identified in primary NSCLCs and were infrequent in cell lines. Focal or broad chromosomal deletions involving FOXA2 were not present. The promoter region of FOXA2 had evidence of hypermethylation, with an inverse correlation between FOXA2 mRNA expression and presence of CpG dinucleotide methylation (p< 0.0001). In primary NSCLC tumor specimens, there was a high frequency of either absence (42/173, 24.2%) or no/low expression (96/173, 55.4%) of Foxa2. In 130 patients with stage I NSCLC there was a trend towards decreased survival in tumors with no/low expression of Foxa2 (HR of 1.6, 95%CI 0.9-3.1; p= 0.122). Conclusions: Loss of expression of Foxa2 is frequent in lung cancer cell lines and NSCLCs. The main mechanism of downregulation of Foxa2 is epigenetic silencing through promoter hypermethylation. Further elucidation of the involvement of Foxa2 and other airway transcription factors in the pathogenesis of lung cancer may identify novel therapeutic targets.

KW - Adenocarcinoma

KW - Downregulation

KW - Epigenetic

KW - Foxa2

KW - Lung cancer

KW - Methylation

KW - Mutation

KW - Non-small-cell lung cancer

KW - Prognosis

KW - Transcription factors

UR - http://www.scopus.com/inward/record.url?scp=84861738981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861738981&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2012.01.011

DO - 10.1016/j.lungcan.2012.01.011

M3 - Article

C2 - 22341411

AN - SCOPUS:84861738981

VL - 77

SP - 31

EP - 37

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -